Search Results for "Mirrx Therapeutics"

17:23 EST 25th January 2015 | BioPortfolio

Original Source: Mirrx Therapeutics

Mirrx Therapeutics is developing a novel microRNA-blocking technology, Blockmirs, which are antisense oligonucleotides that bind to a microRNA binding site on an mRNA. This unique approach blocks single microRNA:mRNA interactions, resulting in extremely targeted regulation of specific mRNAs, thereby potentially reducing unintended effects on gene activity. www.mirrx.com

Matching Channels

None

Matching News

Edema - Pipeline Review, H2 2014

Recently added to the BioPortfolio report store, Edema - Pipeline Review, H2 2014 is a new report from Global Markets Direct published on 2014-12-30. This 40-page report is available in PDF from $200...

Ischemia - Pipeline Review, H2 2014

Recently added to the BioPortfolio report store, Ischemia - Pipeline Review, H2 2014 is a new report from Global Markets Direct published on 2014-12-30. This 228-page report is available in PDF from ...

Matching PubMed Articles

None

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement